Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Satoshi Shakado

Showing results (71-80 of 87) with videos related to

Pageof 9
Sort By:
Hepatology International|January 5, 2021
Elobixibat, an ileal bile acid transporter inhibitor, ameliorates non-alcoholic steatohepatitis in miceRyo Yamauchi, Hidetoshi Takedatsu, Keiji Yokoyama, et al.
Internal Medicine (Tokyo, Japan)|October 21, 2021
Eosinophilic Granuloma of the Liver Mimicking Metastatic Liver TumorYotaro Uchida, Keiji Yokoyama, Tomotaka Higashi, et al.
Intestinal Research|August 10, 2023
Malnutrition and inflammation status in nonobese patients with inflammatory bowel disease are associated with nonalcoholic fatty liver disease: a retrospective studyTakahiro Nagata, Sadahiro Funakoshi, Daisuke Morihara, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|September 6, 2022
A combination of hepatic encephalopathy and body mass index was associated with the point of no return for improving liver functional reserve after sofosbuvir/velpatasvir treatment in patients with hepatitis C virus-related decompensated cirrhosisTomoya Sano, Keisuke Amano, Tatsuya Ide, et al.
Clinical Journal of Gastroenterology|July 21, 2015
A case of hepatitis C-associated osteosclerosis that was improved with the combination therapy of peginterferon alfa-2b and ribavirinSatoshi Shakado, Yuko Akehi, Kaoru Yotsumoto, et al.
Hepato-Gastroenterology|July 16, 2015
Pilot Study of Hepatic Arterial Infusion Chemotherapy with Interferon-beta and 5-fluorouracil: A New Chemotherapy for Patients with Advanced Hepatocellular CarcinomaSatoshi Shakado, Kaoru Iwata, Naoaki Tsuchiya, et al.
Journal of Gastroenterology and Hepatology|May 31, 2019
IL28B gene polymorphism is correlated with changes in low-density lipoprotein cholesterol levels after clearance of hepatitis C virus using direct-acting antiviral treatmentDaisuke Morihara, Yi-Ling Ko, Kumiko Shibata, et al.
Clinical Journal of Gastroenterology|July 17, 2015
Eosinophilic gastroenteritis in a patient with chronic hepatitis C who received treatment with pegylated interferonGenryu Hirano, Atsushi Fukunaga, Tetsuro Sohda, et al.
Journal of Gastroenterology and Hepatology|May 31, 2025
Comparison Analysis of Lenvatinib Plus Transcatheter Arterial Chemoembolization Versus Atezolizumab Plus Bevacizumab as First-Line Therapy for Intermediate-Stage Hepatocellular Carcinoma Beyond the Up-to-Seven CriteriaTakashi Niizeki, Seiichi Mawatari, Michihiko Shibata, et al.
European Journal of Gastroenterology & Hepatology|November 6, 2014
Adjusting the starting dose of telaprevir according to renal function decreases adverse effects and affects the sustained virological response rateDaisuke Morihara, Hiroshi Watanabe, Kazuhide Takata, et al.
Pageof 9

Showing results (71-80 of 87) with videos related to

Sort By:
Pageof 9
Hepatology International|January 5, 2021
Elobixibat, an ileal bile acid transporter inhibitor, ameliorates non-alcoholic steatohepatitis in miceRyo Yamauchi, Hidetoshi Takedatsu, Keiji Yokoyama, et al.
Internal Medicine (Tokyo, Japan)|October 21, 2021
Eosinophilic Granuloma of the Liver Mimicking Metastatic Liver TumorYotaro Uchida, Keiji Yokoyama, Tomotaka Higashi, et al.
Intestinal Research|August 10, 2023
Malnutrition and inflammation status in nonobese patients with inflammatory bowel disease are associated with nonalcoholic fatty liver disease: a retrospective studyTakahiro Nagata, Sadahiro Funakoshi, Daisuke Morihara, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|September 6, 2022
A combination of hepatic encephalopathy and body mass index was associated with the point of no return for improving liver functional reserve after sofosbuvir/velpatasvir treatment in patients with hepatitis C virus-related decompensated cirrhosisTomoya Sano, Keisuke Amano, Tatsuya Ide, et al.
Clinical Journal of Gastroenterology|July 21, 2015
A case of hepatitis C-associated osteosclerosis that was improved with the combination therapy of peginterferon alfa-2b and ribavirinSatoshi Shakado, Yuko Akehi, Kaoru Yotsumoto, et al.
Hepato-Gastroenterology|July 16, 2015
Pilot Study of Hepatic Arterial Infusion Chemotherapy with Interferon-beta and 5-fluorouracil: A New Chemotherapy for Patients with Advanced Hepatocellular CarcinomaSatoshi Shakado, Kaoru Iwata, Naoaki Tsuchiya, et al.
Journal of Gastroenterology and Hepatology|May 31, 2019
IL28B gene polymorphism is correlated with changes in low-density lipoprotein cholesterol levels after clearance of hepatitis C virus using direct-acting antiviral treatmentDaisuke Morihara, Yi-Ling Ko, Kumiko Shibata, et al.
Clinical Journal of Gastroenterology|July 17, 2015
Eosinophilic gastroenteritis in a patient with chronic hepatitis C who received treatment with pegylated interferonGenryu Hirano, Atsushi Fukunaga, Tetsuro Sohda, et al.
Journal of Gastroenterology and Hepatology|May 31, 2025
Comparison Analysis of Lenvatinib Plus Transcatheter Arterial Chemoembolization Versus Atezolizumab Plus Bevacizumab as First-Line Therapy for Intermediate-Stage Hepatocellular Carcinoma Beyond the Up-to-Seven CriteriaTakashi Niizeki, Seiichi Mawatari, Michihiko Shibata, et al.
European Journal of Gastroenterology & Hepatology|November 6, 2014
Adjusting the starting dose of telaprevir according to renal function decreases adverse effects and affects the sustained virological response rateDaisuke Morihara, Hiroshi Watanabe, Kazuhide Takata, et al.
Pageof 9